About Breast Cancer mAbs
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.
Technavio’s analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Amgen
• Roche
• Mylan
Other prominent vendors
• Array BioPharma
• AstraZeneca
• Biocad
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celldex Therapeutics
• Celltrion
• Chugai Pharmaceutical
• Daiichi Sankyo
• DARA Biosciences
• Eddingpharm
• Eisai
• Galena Biopharma
• GlaxoSmithKline
• Halozyme Therapeutics
• Hospira
• ImmunoGen
• Immunomedics
• MacroGenics
• Merck
• Novartis
• Oncothyreon
• Pfizer
• ProStrakan
• Puma Biotechnology
• Seattle Genetics
• Sun Pharmaceutical Industries
• Synta Pharmaceuticals
• Teva Pharmaceuticals
Market driver
• Reimbursement benefits for breast cancer mAbs
• For a full, detailed list, view our report
Market challenge
• Absence of adequate diagnosis and screening procedures for early detection
• For a full, detailed list, view our report
Market trend
• Emergence of targeted and combination therapies for breast cancer
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Breast cancer: Overview
• Understanding the disease
• Treatment regimen for breast cancer
• Overview of mAbs
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs
PART 09: Market segmentation by end-user
• Hospitals
• Retail pharmacies
PART 10: Geographical segmentation
• Global breast cancer mAbs market by geographical segmentation 2015-2020
• Breast cancer mAbs market in Americas
• Breast cancer mAbs market in EMEA
• Breast cancer mAbs market in APAC
PART 11: Market drivers
• Reimbursement benefits for breast cancer mAbs
• Increase in demand for breast cancer ADCs
• Huge market potential for breast cancer mAbs owing to product approvals
• Exposure to risk factors
PART 12: Impact of drivers
PART 13: Market challenges
• Absence of adequate diagnosis and screening procedures for early detection
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs
• Difficulties in patient recruitment for conducting clinical trials
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Emergence of targeted and combination therapies for breast cancer
• Growing focus of vendors on untapped markets
• Emergence of biosimilars
• Outsourcing of biosimilar manufacturing activities
• Need for high investment in R&D
PART 16: Vendor landscape
• Competitive scenario
• Key news
• Roche
• Amgen
• Mylan
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global breast cancer mAbs market snapshot
Exhibit 03: Key buying criteria for breast cancer mAbs 2015
Exhibit 04: Impact of key customer segments on market 2015
Exhibit 05: Breast cancer stages based on tumor size and extent of metastasis
Exhibit 06: Classification of breast cancer based on genetic make-up of tumor cells
Exhibit 07: Treatment regimen for breast cancer
Exhibit 08: Comparison of small molecules and mAbs
Exhibit 09: Preparation of mAbs
Exhibit 10: Global breast cancer mAbs market: Key metrics analysis snapshot
Exhibit 11: Global breast cancer mAbs market: Pipeline snapshot 2015
Exhibit 12: Pipeline portfolio: Global breast cancer mAbs market 2015
Exhibit 13: Developmental history of trastuzumab biosimilars in various countries
Exhibit 14: Global breast cancer mAbs market snapshot: Developed and emerging markets 2015
Exhibit 15: Global breast cancer mAbs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global breast cancer mAbs market 2015
Exhibit 17: Timeline for development of breast cancer mAbs
Exhibit 18: Impact of drivers and challenges of global breast cancer mAbs market
Exhibit 19: Five forces analysis
Exhibit 20: Approved naked mAbs by US FDA and EU
Exhibit 21: Global breast cancer mAbs market segmentation by type of molecule 2015
Exhibit 22: Global breast cancer mAbs market segmentation by end-user 2015
Exhibit 23: Global breast cancer mAbs market: Geographical outlook 2015-2020
Exhibit 24: Global breast cancer mAbs market: Geographical outlook 2015
Exhibit 25: Revenue/growth outlook in different countries/regions 2015
Exhibit 26: Global breast cancer mAbs market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 27: Opportunity analysis of breast cancer mAbs market in Americas
Exhibit 28: Breast cancer mAbs market in Americas 2015-2020 ($ billions)
Exhibit 29: Breast cancer mAbs market in Americas by country 2015
Exhibit 30: Opportunity analysis of breast cancer mAbs market in EMEA
Exhibit 31: Breast cancer mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 32: Opportunity analysis of breast cancer mAbs market in APAC
Exhibit 33: Number of individuals treated with Herceptin through patient assistance programs in China 2011-2014
Exhibit 34: Breast cancer mAbs market in APAC 2015-2020 ($ billions)
Exhibit 35: Global breast cancer mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 36: Impact of drivers
Exhibit 37: Five-year survival rate by stage of diagnosis
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Global breast cancer mAbs market: Impact assessment of key trends
Exhibit 40: Competitive assessment of vendors
Exhibit 41: Key vendors: Geographical presence 2015
Exhibit 42: Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 43: Roche: Geographical segmentation of Avastin by revenue 2015
Exhibit 44: Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 45: Roche: Geographical segmentation of Herceptin 2015
Exhibit 46: Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 47: Roche: Geographical segmentation of Perjeta 2015
Exhibit 48: Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 49: Roche: Geographical segmentation of Kadcyla 2015
Exhibit 50: Roche: Metrics analysis
Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 52: Amgen: Geographical segmentation of Xgeva 2015
Exhibit 53: Amgen: Metrics analysis
Exhibit 54: Mylan: Business segmentation by revenue 2015
Exhibit 55: Mylan: Geographical segmentation by revenue 2015 (generics segment)
Exhibit 56: Mylan: Metrics analysis
